Keros Therapeutics (NASDAQ:KROS) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Keros Therapeutics (NASDAQ:KROSFree Report) in a research note released on Tuesday morning, Benzinga reports. They currently have a $100.00 price objective on the stock.

KROS has been the subject of a number of other reports. Truist Financial restated a buy rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Wednesday, March 13th. William Blair restated an outperform rating on shares of Keros Therapeutics in a report on Wednesday, February 21st. Piper Sandler restated an overweight rating and issued a $105.00 target price on shares of Keros Therapeutics in a report on Wednesday, March 27th. Finally, Wedbush restated an outperform rating and issued a $86.00 target price on shares of Keros Therapeutics in a report on Thursday, February 29th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of Buy and an average target price of $86.00.

View Our Latest Stock Report on Keros Therapeutics

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $45.41 on Tuesday. The company has a market cap of $1.64 billion, a PE ratio of -8.82 and a beta of 1.24. Keros Therapeutics has a 12 month low of $27.02 and a 12 month high of $73.00. The company has a 50-day simple moving average of $52.69 and a 200-day simple moving average of $53.73.

Keros Therapeutics (NASDAQ:KROSGet Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.12. The company had revenue of $0.08 million during the quarter. During the same period last year, the firm posted ($1.26) EPS. The business’s revenue for the quarter was down 97.3% compared to the same quarter last year. On average, analysts anticipate that Keros Therapeutics will post -4.97 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently bought and sold shares of KROS. ADAR1 Capital Management LLC purchased a new stake in Keros Therapeutics during the fourth quarter worth approximately $27,367,000. Redmile Group LLC acquired a new position in shares of Keros Therapeutics during the first quarter worth $36,576,000. Darwin Global Management Ltd. lifted its position in shares of Keros Therapeutics by 35.4% during the first quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock worth $95,060,000 after purchasing an additional 375,523 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Keros Therapeutics by 47.9% during the fourth quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after purchasing an additional 226,674 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Keros Therapeutics by 18.8% during the third quarter. Vanguard Group Inc. now owns 1,406,431 shares of the company’s stock worth $44,837,000 after purchasing an additional 222,652 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Further Reading

Analyst Recommendations for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.